• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Venus Concept Inc.

    8/16/24 8:00:42 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email
    S-8 1 ef20034083_s8.htm S-8
    As filed with the Securities and Exchange Commission on August 16, 2024
    Registration No. 333-

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    FORM S-8
    REGISTRATION STATEMENT
    UNDER
    THE SECURITIES ACT OF 1933

    Venus Concept Inc.
    (Exact name of Registrant as specified in its charter)

    Delaware
     
    06-1681204
    (State or other jurisdiction of incorporation or organization)
     
    (I.R.S. Employer Identification Number)
       
    235 Yorkland Blvd, Suite 900,
    Toronto, Ontario
     
    M2J 4Y8
    (Address of Principal Executive Offices)
     
    (Zip Code)

    Venus Concept Inc. 2019 Incentive Award Plan
    (Full Title of the Plan)

    Michael Mandarello
    General Counsel and Corporate Secretary
    Venus Concept Inc.
    235 Yorkland Boulevard, Suite 900
    Toronto, Ontario M2J 4Y8
    (877) 848-8430
    (Name, address, including zip code, and telephone number, including area code, of agent for service)

    Copies to:
    Richard Raymer, Esq.
    Dorsey & Whitney LLP
    161 Bay Street, Suite 4310
    Toronto, ON M5J 2S1
    Telephone: (416) 367-7388

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

    Large accelerated filer
    ☐
     
    Accelerated filer
    ☐
    Non-accelerated filer
    ☒
     
    Smaller reporting company
    ☒
         
    Emerging growth company
    ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐



    EXPLANATORY NOTE
     
    This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 221,165 shares of Common Stock of Venus Concept Inc. (the “Registrant”) issuable under the Venus Concept Inc. 2019 Incentive Award Plan (the “2019 Plan”), none of which have been issued as of the date of this Registration Statement. These additional shares of Common Stock are securities of the same class as other securities for which the original registration statement on Form S-8 was filed with the Securities and Exchange Commission (the “SEC”) on December 13, 2019 (File No. 333-235480) and remains effective.
     
    These additional shares of Common Stock have become reserved for issuance as a result of the operation of the automatic annual increase provision of the 2019 Plan. The 2019 Plan provides that the total number of shares subject to such plan will be increased annually on the first day of each year, beginning in 2020 and ending in 2029, by an amount equal to the lesser of (A) four percent (4%) of the shares of the Registrant’s Common Stock outstanding on the last day of the immediately preceding fiscal year and (B) such smaller number of Shares as determined by the Board of Directors.


    INCORPORATION BY REFERENCE OF CONTENTS
    OF REGISTRATION STATEMENTS ON FORM S-8
     
    Pursuant to General Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the SEC on December 13, 2019 (File No. 333-235480), August 14, 2020 (File No. 333-246083), April 9, 2021 (File No. 333-255159), April 8, 2022 (File No. 333-264203) and May 26, 2023 (File No. 333-272235) are incorporated by reference herein.
     
    Item 8.
    Exhibits.
     
    Reference is made under this Item 8 to the exhibit index included in this Registration Statement.
     
    Exhibit Index
     
           
    Incorporated by Reference
           
    Exhibit
    Number
     
    Exhibit Description
     
    Form
     
    Date
     
    Number
     
    Filed
    Herewith
    4.1
     
    Amended and Restated Certificate of Incorporation.
     
    8-K
     
    10-17-17
     
    3.1
       
                         
    4.2
     
    Certificate of Amendment of Certificate of Incorporation.
     
    8-K
     
    11-7-19
     
    3.1
       
                         
    4.3
     
    Certificate of Amendment of Certificate of Incorporation
     
    8-K
     
    05-11-23
     
    3.1
       
                         
    4.4
     
    Second Amended and Restated Bylaws.
     
    8-K
     
    11-7-19
     
    3.2
       
                         
    4.5
     
    Description of Securities.
     
    10-K
     
    3-29-21
     
    4.1
       
                         
    4.6
     
    Form of Common Stock Certificate.
     
    S-1/A
     
    9-18-17
     
    4.2
       
                         
    4.7
     
    Venus Concept Inc. 2019 Incentive Award Plan. #
     
    8-K
     
    11-7-19
     
    10.21
       
                         
    4.8
     
    Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Incentive Award Plan. #
     
    10-K
     
    3-30-20
     
    10.24
       
                         
    4.9
     
    Form of Restricted Stock Unit Notice and Agreement under the 2019 Incentive Award Plan #
     
    S-8
     
    04-8-22
     
    4.8
       
                         
    5.1
     
    Opinion of Dorsey & Whitney LLP
                 
    X
                         
    23.1
     
    Consent of MNP LLP, independent registered public accounting firm.
                 
    X
                         
    23.2
     
    Consent of Dorsey & Whitney LLP (included in Exhibit 5.1).
                 
    X
                         
    24.1
     
    Power of Attorney. Reference is made to the signature page to the Registration Statement.
                 
    X
                         
    107
     
    Filing Fee Table
                 
    X
                         
    #
     
    Indicates management contract or compensatory plan.
                   


    SIGNATURES
     
    Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in Toronto, Province of Ontario, Canada, on this 16th day of August, 2024.

     
    Venus Concept Inc.
         
     
    By:
    /s/ Rajiv De Silva
       
    Rajiv De Silva
       
    Chief Executive Officer
     

    POWER OF ATTORNEY
     
    KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below does hereby constitute and appoint Rajiv De Silva and Domenic Della Penna and each of them, with full power of substitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act for him or her in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file this registration statement, with all exhibits thereto, and other documents in connection therewith, with the SEC, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in order to effectuate the same as fully, to all intents and purposes, as they or he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or any of them, may lawfully do or cause to be done by virtue hereof.
     
    Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the date indicated.
     
    Signature
     
    Title
     
    Date
             
    /s/ Rajiv De Silva
     
    Chief Executive Officer and Director
    (Principal Executive Officer)
     
    August 16, 2024
    Rajiv De Silva
       
             
             
    /s/ Domenic Della Penna
     
    Chief Financial Officer
    (Principal Financial and Accounting Officer)
     
    August 16, 2024
    Domenic Della Penna
       
             
             
    /s/ Scott Barry
     
    Chairman and Director
     
    August 16, 2024
    Scott Barry
       
             
    /s/ Garheng Kong, M.D.
     
    Director
     
    August 16, 2024
    Garheng Kong, M.D.
       
             
    /s/ Louise Lacchin
     
    Director
     
    August 16, 2024
    Louise Lacchin
       
             
    /s/ Fritz LaPorte
     
    Director
     
    August 16, 2024
    Fritz LaPorte
       
             
    /s/ Anthony Natale, M.D.
     
    Director
     
    August 16, 2024
    Anthony Natale, M.D.
       
             
    /s/ Keith Sullivan
     
    Director
     
    August 16, 2024
    Keith J. Sullivan
       
         
    /s/ S.Tyler Hollmig, M.D.
     
    Director
     
    August 16, 2024
    S.Tyler Hollmig, M.D.
       
         



    Get the next $VERO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    SEC Filings

    View All

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 POS filed by Venus Concept Inc.

    S-8 POS - Venus Concept Inc. (0001409269) (Filer)

    2/6/26 4:47:21 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Venus Concept Announces Third Quarter 2025 Financial Results

    TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three and nine months ended September 30, 2025. Summary of Financial Results & Recent Progress: Energy Based Device ("EBD") revenues showing signs of stabilization. Total EBD systems sales of $9.6 million, up 2% year over year Total revenue for the third quarter of $13.8 million, down 8% year-over-year and down 12% quarter-over-quarter. Primarily driven by a decline in the Hair Restoration business (the "Venus Hair Business") impacted by a delay in the pending sale. Third

    11/13/25 7:00:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Receives 510(k) for the Venus NOVA, Its Most Advanced Multi-Application Platform for Non-Invasive Body and Skin Treatments

    TORONTO, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company"), a global leader in medical aesthetic technology, announced today that it has received a 510(k) clearance from the U.S. Food and Drug Administration ("FDA") to market the Venus NOVA™, the Company's next-generation multi-application platform designed to redefine non-invasive treatments for the body, face, and skin. Venus NOVA integrates Adaptive Electrical Muscle Stimulation (EMS), proprietary (MP)² combining Multi-Polar Radio Frequency (RF) with Pulsed Electromagnetic Fields (PEMF), and Advanced VariPulse™ technology -delivering a powerful, comprehensive solution for body contouring, muscle co

    11/10/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Announces $11.48 Million Debt-to-Equity Exchange Transaction

    TORONTO, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that, on September 30, 2025, the Company exchanged the full $11.48 million balance of its subordinated convertible notes held by affiliates of Madryn Asset Management, LP ("Madryn") for 545,335 shares of its Series Y preferred stock. Following the transaction, the Company had total debt obligations of approximately $30.1 million, a reduction of 24% compared to $39.7 million outstanding as of December 31, 2024. "Madryn's invaluable partnership has provided us with financial flexibility as we work towards sustained long

    10/2/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    10/2/25 7:23:29 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    7/2/25 7:27:23 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Large owner Madryn Asset Management, Lp

    4 - Venus Concept Inc. (0001409269) (Issuer)

    4/2/25 5:47:31 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/8/24 7:51:38 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

    SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

    10/3/24 7:59:41 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

    SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

    9/30/24 9:53:26 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    View All

    Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

    TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

    10/12/23 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

    TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

    10/11/22 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    $VERO
    Financials

    Live finance-specific insights

    View All

    Venus Concept to Release Third Quarter of Fiscal Year 2025 Financial Results on November 13, 2025

    TORONTO, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, November 13, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (+1 201-389-0925 for international callers) and provide access code 13756285. A live webcast of the call will also be provided on the investor relations section of the Com

    10/1/25 4:05:00 PM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release Second Quarter of Fiscal Year 2025 Financial Results on August 14, 2025

    TORONTO, July 16, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that second quarter of fiscal year 2025 financial results will be released after the market closes on Thursday, August 14, 2025. Management will host a conference call at 5:00 p.m. Eastern Time on August 14, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13754867. A live webcast of the call will also be provided on the investor relations section of the Company's

    7/16/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care

    Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

    TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

    4/7/25 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care